Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways.

Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE, Glynn SA.

Oncotarget. 2017 Jul 26;8(46):80568-80588. doi: 10.18632/oncotarget.19631. eCollection 2017 Oct 6.

2.

Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes.

Walsh EM, Keane MM, Wink DA, Callagy G, Glynn SA.

Crit Rev Oncog. 2016;21(5-6):333-351. doi: 10.1615/CritRevOncog.2017021307.

3.

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Breast Cancer Res. 2015 Feb 22;17:25. doi: 10.1186/s13058-015-0527-x.

4.

Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.

Jeon M, Han J, Nam SJ, Lee JE, Kim S.

Chem Biol Interact. 2016 Oct 25;258:126-33. doi: 10.1016/j.cbi.2016.08.021. Epub 2016 Aug 25.

PMID:
27567548
5.

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.

Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL.

Int J Cancer. 2014 May 15;134(10):2424-36. Erratum in: Int J Cancer. 2014 Oct 1;135(7):E6.

6.

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.

Liubomirski Y, Lerrer S, Meshel T, Morein D, Rubinstein-Achiasaf L, Sprinzak D, Wiemann S, Körner C, Ehrlich M, Ben-Baruch A.

Front Immunol. 2019 Apr 24;10:804. doi: 10.3389/fimmu.2019.00804. eCollection 2019.

7.
8.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.

Shapira I, Lee A, Vora R, Budman DR.

Crit Rev Oncol Hematol. 2013 Nov;88(2):284-92. doi: 10.1016/j.critrevonc.2013.05.003. Epub 2013 Jun 5. Review.

PMID:
23755891
9.

The TGFα-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells.

Ignacio RMC, Gibbs CR, Lee ES, Son DS.

Oncotarget. 2018 Jun 29;9(50):29286-29303. doi: 10.18632/oncotarget.25389. eCollection 2018 Jun 29.

10.

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M, Zhang Q.

Target Oncol. 2014 Dec;9(4):349-57.

PMID:
24233638
11.

Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

Shen M, Jiang YZ, Wei Y, Ell B, Sheng X, Esposito M, Kang J, Hang X, Zheng H, Rowicki M, Zhang L, Shih WJ, Celià-Terrassa T, Liu Y, Cristea I, Shao ZM, Kang Y.

Cancer Cell. 2019 Jan 14;35(1):64-80.e7. doi: 10.1016/j.ccell.2018.11.016. Epub 2019 Jan 3.

PMID:
30612941
12.

Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.

Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, Amano S, Nemoto N.

Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.

PMID:
26009308
13.

Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.

Apaya MK, Shiau JY, Liao GS, Liang YJ, Chen CW, Yang HC, Chu CH, Yu JC, Shyur LF.

J Exp Clin Cancer Res. 2019 May 9;38(1):187. doi: 10.1186/s13046-019-1187-y.

14.

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.

Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, MacKeigan JP, Filipp FV, Graveel CR.

Cancer Metab. 2017 Aug 22;5:6. doi: 10.1186/s40170-017-0168-x. eCollection 2017.

15.

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Shields S, Conroy E, O'Grady T, McGoldrick A, Connor K, Ward MP, Useckaite Z, Dempsey E, Reilly R, Fan Y, Chubb A, Matallanas DG, Kay EW, O'Connor D, McCann A, Gallagher WM, Coppinger JA.

Oncotarget. 2018 Feb 28;9(21):15673-15690. doi: 10.18632/oncotarget.24590. eCollection 2018 Mar 20. Erratum in: Oncotarget. 2019 May 3;10(33):3144.

16.

Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis.

Baldassarre T, Watt K, Truesdell P, Meens J, Schneider MM, Sengupta SK, Craig AW.

Mol Cancer Res. 2015 Jun;13(6):1044-55. doi: 10.1158/1541-7786.MCR-14-0573. Epub 2015 Mar 17.

17.

Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.

Julovi SM, Martin JL, Baxter RC.

Front Endocrinol (Lausanne). 2018 Mar 22;9:120. doi: 10.3389/fendo.2018.00120. eCollection 2018.

18.

Triple-negative breast cancer: current state of the art.

Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.

Tumori. 2010 Nov-Dec;96(6):875-88. Review.

PMID:
21388048
19.

Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.

Liang S, Chen Z, Jiang G, Zhou Y, Liu Q, Su Q, Wei W, Du J, Wang H.

Cancer Lett. 2017 Feb 1;386:12-23. doi: 10.1016/j.canlet.2016.11.003. Epub 2016 Nov 9. Erratum in: Cancer Lett. 2017 Nov 15;:.

PMID:
27836733
20.

Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.

Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA.

Breast Cancer Res. 2012 Sep 12;14(5):R125. doi: 10.1186/bcr3319.

Supplemental Content

Support Center